CMPSCOMPASS Pathways plc

Nasdaq compasspathways.com


$ 6.73 $ -0.06 (-0.88 %)    

Thursday, 05-Sep-2024 15:17:49 EDT
QQQ $ 459.86 $ 0.43 (0.09 %)
DIA $ 407.95 $ -1.96 (-0.48 %)
SPY $ 548.56 $ -1.34 (-0.24 %)
TLT $ 99.56 $ 0.56 (0.57 %)
GLD $ 232.35 $ 1.92 (0.83 %)
$ 6.725
$ 6.85
$ 6.73 x 184
$ 6.75 x 100
$ 6.71 - $ 6.99
$ 5.01 - $ 12.75
543,686
na
459.91M
$ 1.53
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-29-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 02-24-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 shake-up-at-lykos-therapeutics-after-fda-blocks-ecstasy-based-treatment-ceo-steps-down

Lykos Therapeutics CEO Amy Emerson steps down following the FDA's rejection of the company's MDMA-based PTSD therapy.

 psychedelic-drugs-market-set-to-grow-by-137b-by-2028-driven-by-mental-health-disorders-and-ai-integration

The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI adva...

 hc-wainwright--co-reiterates-buy-on-compass-pathways-maintains-120-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $120 pri...

 canaccord-genuity-maintains-buy-on-compass-pathways-lowers-price-target-to-48

Canaccord Genuity analyst Sumant Kulkarni maintains Compass Pathways (NASDAQ:CMPS) with a Buy and lowers the price target fr...

 hc-wainwright--co-reiterates-buy-on-compass-pathways-maintains-120-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $120 pri...

 rbc-capital-initiates-coverage-on-compass-pathways-with-outperform-rating-announces-price-target-of-23

RBC Capital analyst Leonid Timashev initiates coverage on Compass Pathways (NASDAQ:CMPS) with a Outperform rating and announ...

Core News & Articles

https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted...

 cantor-fitzgerald-reiterates-overweight-on-compass-pathways

Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.

Core News & Articles

https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after...

 whats-going-on-with-mindmed-and-psychedelic-stocks

Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approv...

Core News & Articles

https://www.marijuanamoment.net/top-federal-drug-official-says-theres-tremendous-excitement-around-psych

 hc-wainwright--co-reiterates-buy-on-compass-pathways-maintains-120-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $120 pri...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION